bone mass significantly increased with suppressed bone resorption in early life of rats fed with AIN-93G semi-purified diets supplemented with 10% whole blueberry (BB) powder for 2 weeks. However, the effects of increased phenolic acids in animal serum due to this diet on bone and bone resorption were unclear. This in vitro and in ex vivo study examined the effects of phenolic hippuric acid (HA) and 3-(3-hydroxyphenyl) propionic acid (3-3-PPA) on osteoclastic cell differentiation and bone resorption. We cultured murine osteoclast (macrophage) cell line, RAW 264.7 cells, and hematopoietic osteoclast progenitor cells (isolated from 4-week-old C57BL6/J mice) with 50 ng/ml of receptor activator of nuclear factor κ-Β ligand (RANKL). Morphologic studies showed decreased osteoclast number with treatment of 2.5% mouse serum from BB diet-fed animals compared with those treated with serum from standard casein diet-fed mice in both RAW 264.7 cell and primary cell cultures. HA and 3-3-PPA, but not 3-4-PPA, had dose-dependent suppressive effects on osteoclastogenesis and osteoclast resorptive activity in Corning osteo-assay plates. Signaling pathway analysis showed that after pretreatment with HA or 3-3-PPA, RANKLstimulated increase of osteoclastogenic markers, such as nuclear factor of activated T-cells, cytoplasmic 1 and matrix metallopeptidase 9 gene/protein expression were blunted. Inhibitory effects of HA and 3-3-PPA on osteoclastogenesis utilized RANKL/ RANK independent mediators. The study revealed that HA and 3-3-PPA significantly inhibited osteoclastogenesis and bone osteoclastic resorptive activity.
| INTRODUCTION
Physiologic bone development, growth, and repair are coordinated by well-balanced bone formation and resorption, and this coordination is influenced by factors including nutrition, hormones, and weight bearing/physical activity (Office of the Surgeon General, US, 2004; Shams-White et al., 2018; Tan et al., 2014) . For nutritional factors, consideration has been closely directed to micronutrients, such as calcium, vitamin D, and phosphate, and to macronutrients, such as proteins and fats. Moreover, functional dietary factors from dairy products, fruits and vegetables, and foods contributing to acidbase balance interact with local bone transcription factors and circulating endogenous hormones to facilitate bone development (Yan et al., 2016) . It is of interest to identify specific bioactive compounds. Previous studies have shown that bone mass and size in early pubertal children are significantly dependent on intake of fruits and vegetables (Hardcastle, Aucott, Reid, & Macdonald, 2011; Lanham, 2006; Tylavsky et al., 2004) . We have previously described the robust effect of a 10% blueberry (BB)-supplemented diet on the promotion of bone formation in young male and female rats (Chen et al., 2010) . We hypothesized that the significant effects of BB diet on bone mass increase in rapidly growing rats may be associated with increased phenolic acid levels in blood to inhibit osteoclastic bone resorption and to stimulate osteoblast differentiation.
Phenolic acids (PAs), such as hippuric acid (HA) and 3-(3-hydroxyphenyl) propionic acid (3-3-PPA), are metabolites derived from BB pigment polyphenols that appear in the serum of BB-fed rats. These molecules have been recently characterized as bioactive in stimulating osteoblast activity and dose-dependently increasing bone mass in mice . HA and 3-3-PPA are produced by gut microflora through the breakdown of chlorogenic acid and are thereafter absorbed and oxidized in the liver before entering circulation (Marín, Miguélez, Villar & Lombó, 2015) . Until recently, these small molecules were not known for functions on stimulating or inhibiting particular cell differentiation or activity; moreover, it has not been proposed that HA and 3-3-PPA suppress osteoclastic bone resorption.
Periods of rapid osteoblastic bone formation are essential early in life as well as in adulthood to maintain skeletal health whereas osteoclastic bone resorption is essential to shape and keep an appropriate amount of bone (Clarke, 2008) . While osteoclastic bone resorption is an important physiological cellular function in skeletal development, suppression of osteoclastogenesis is effective as a therapeutic approach to bone-destructive diseases such as osteoporosis and rheumatoid arthritis. Osteoblasts and osteoclasts originate from different lineage of cells. Osteoblasts are derived from mesenchymal stem cells; osteoclasts are derived from hematopoietic lineage (Grigoriadis et al., 2010) . Osteoclast differentiation and bone resorptive activities of mature osteoclasts are regulated by series of cellular molecules, such as receptor activator of nuclear factor κ-Β ligand (RANKL) and macrophage colony-stimulating factor (Khosla, 2001) . RANKL, a secreted protein, is and thought to be produced chiefly by osteoblasts and also by other cell types such as mesenchymal stromal cells, osteocytes, preadipocytes, and chondrocytes (O'Brien, 2010; Wang et al., 2014) . Secreted RANKL stimulates receptor activator of nuclear factor kappa-B (RANK) signaling (Khosla, 2001) .
The osteoclastogenic signaling starts from binding of RANKL to its receptor RANK on the surface of osteoclast precursors; this binding triggers the recruitment of tumor necrosis factor (TNF) receptor-associated factors (Park, Lee, & Lee, 2017) . The RANK-TNF receptor-associated factor complex activates downstream signal pathways, including the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) and mitogen-activated protein kinase pathways, which lead to the induction and activation of transcription factors such as Fos proto-oncogene (cFos) and nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1; Boyce, 2013) , resulting in enhanced expression of osteoclast-specific genes (Kim et al., 2018; Moreaux et al., 2011) . In the current report, we hypothesize that natural plant-derived PAs, HA, and 3-3-PPA, directly and transcriptionally inhibit cFos and NFATc1 to decrease osteoclastogenesis via a RANKL-RANK independent mechanism.
| MATERIALS AND METHODS

| Cell cultures
Murine osteoclast progenitor macrophage cell line RAW 264.7 cells were commercially obtained (American Type Culture Collection [ATCC], Manassas, VA, http://www.atcc.org; ATCC ® TIB-71 ™ ). Nonadherent bone marrow cells from 4-week-old female C57BL/J mice were isolated.
Bone marrow cells were flushed from femurs and then cultured in T175 flasks (Corning® Cell Culture Flasks; Sigma-Aldrich) for 2 days to let stromal cells attach. Two days later, nonadherent cells were collected and cultured in appropriate plates with appropriate cell densities. These cells are considered as hematopoietic osteoclast progenitor cells (Chen et al., 2005) . Conditional serum for treatment of cells was taken from female rats either fed 10% BB supplemental diet or standard rodent casein diet for 4 weeks as described in our previous study (Chen et al., 2010) . Cell cultures were performed in α-Minimum Essential Medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT), penicillin (100 units/ml), streptomycin (100 µg/ml), and glutamine (4 mM). Cells were seeded in 96-, 12-, or 6-well cell culture plates at appropriate density of cells per well for morphology, RNA, and protein expression experiments. At 85% confluence, cells in 96-well plates were treated with 2.5% rat serum (7.5% FBS) in the presence of 50 ng/ml of soluble RANKL for osteoclastic cell morphologic study.
2.2 | Osteoclast differentiation assay, morphologic tartrate-resistant acid phosphatase staining RAW264.7 cells or nonadherent bone marrow cells were cultured in 96-well plates (2 × 10 4 cells/well) in the presence or absence of 50 ng/ml of RANKL. Cells were treated with HA at four different concentrations, 0.01×, 0.1×, 1×, and 10×, with 1× equivalent to concentration of 60 µg/dl of HA free form appeared in blood after 10% BB supplemental diet in rats (Chen et al., 2010) . Four different concentrations of 3-3-PPA or 3-(4-hydroxyphenyl) propionic acid (3-4-PPA), 0.1×, 1×, 10×, and 100×, with 1× equivalent to concentration of 10 µg/dl of 3-3-PPA or 3-4-PPA free form appeared in blood after 10% BB supplemental diet in rats (Chen et al., 2010 
| Osteoclast resorption activity and proliferation assay
For osteoclast resorption activity assay, RAW264.7 cells or nonadherent bone marrow cells were seeded in six-well collagen-coated plates (BD Biosciences) at a density of 1 × 10 5 cells/well, and cells were treated with 50 ng/ml RANKL for 2-3 days. When osteoclasts begin to differentiate to mature cells on day 3, the cells were dissociated and the same number of osteoclastic cells were cultured onto hydroxyapatite-coated plates (CLS3989; Corning). The cells were treated with different concentrations of HA, 3-3-PPA, and 3-4-PPA, or 2.5% conditional serum for another 48 hr in the presence or absence of RANKL. Cells in the culture plates were fixed using 2.5% glutaraldehyde with or without Von Kossa staining.
The areas of hydroxyapatite resorption were observed by light microscopy and analyzed using the Image J software (imagej.nih.gov/ij/). Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)−2,5-diphenyltetrazolium bromide (MTT) assay. Briefly, fixed cells in the culture plates were washed with phosphate-buffered saline and incubated with MTT (0.5 mg/ml) at 37°C for 3 hr. After rinsing out MTT, 100 µl of dimethylformamide was used to dissolve the reduced formazan crystals, and microplate reader was used to determine the absorbance of each well at 540 nm.
2.4 | RNA isolation, real-time reverse transcription-polymerase chain reaction RAW264.7 cells were cultured in 12-well plates (1.2 × 10 5 cells/well) with or without RANKL (50 ng/ml) in the presence or absence of 1× HA for 1, 2, 3, or 4 days. RNA from cultured cells were extracted using TRI Reagent (MRC Inc., Cincinnati, OH) according to the manufacturerʼs recommendation followed by DNase digestion and column cleanup using QIAGEN mini columns (Chen et al., 2016) . Reverse transcription was carried out using an iScript cDNA Synthesis Kit from Bio-Rad (Hercules, CA). Real-time reverse transcription-polymerase chain reaction (RT-PCR) was carried out using SYBR Green and an ABI 7000 Sequence Detection System (Applied Biosystems, Foster City, CA); gene expression data were normalized by housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (Chen et al., 2016) . All primers for RT-PCR analysis used were designed using Primer Express Software 2.0.0 (Applied Biosystems) and are listed in Table 1. 2.5 | Western blotting RAW264.7 cells were cultured in six-well plates (3.5 × 10 5 cells/ well) with or without RANKL (50 ng/ml) in the presence or absence of 1× HA or 3-3-PPA for 3 days. Total protein extracts were prepared using radioimmunoprecipitation assay buffer (Solarbio). Western blots were performed using standard protocols (Chen, Lazarenko, Blackburn, & Shankar, 2017 (Figure 3c,d) . Interestingly, time-dependent, RANKL-induced MMP9 and Cathepsin K gene expression were significantly inhibited by HA (Figure 3c,d) .
Moreover, on days 2, 3, and 4, compared to untreated control, HA significantly inhibited MMP9 gene expression ( Figure 3c ), and HA significantly inhibited Cathepsin K gene expression below to basal level (untreated control) on days 1, 2, and 3 (Figure 3d ). RAW264.7 cells were cultured in six-well plates and cells were treated with or without 1× HA or 1× 3-3-PPA in the presence or absence of RANKL for 3 days. Proteins were isolated for Western blot analysis. It is very clear that RANKL increased NFATc1, cFos, MMP9, and Cathepsin K protein expression ( Figure 4a ). Compared to untreated control, HA and 3-3-PPA inhibited NFATc1, cFos, MMP9, and Cathepsin K protein expression ( Figure 4a ). It is even more clear that both HA and 3-3-PPA significantly inhibited RANKL-induced NFATc1, cFos, MMP9, and Cathepsin K protein expression ( Figure 4a ). There are not many signaling pathways that could (a) regulate both osteoblast and osteoclast activity, however, β-catenin is one of these signaling molecules. We therefore next checked if HA and 3-3-PPA regulate β-catenin signaling in pre-osteoclasts. We 3.3 | HA and 3-3-PPA inhibit GPR109A expression to increased intracellular cAMP in RAW264.7 cells HA and 3-3-PPA are known structurally similar to nicotinic acid or niacin (vitamin B3), and nicotinic acid is reported to bind to GPR109A (Goel & Dunbar, 2016) . GPR109A is abundantly expressed in macrophages and in mature osteoclast ( Independent experiments were repeated more than three times, obtaining similar results each time, *significant differences versus control by t test, dose response were assessed using Cruzickʼs nonparametric test for trend. RANKL, receptor activator of nuclear factor κ-Β ligand different concentrations of HA or 3-3-PPA. Surprisingly, HA and 3-3-PPA both dose-dependently suppressed GPR109A gene expression ( Figure 6a,b ). GPR109A protein expression levels were also investigated, and we found both HA and 3-3-PPA suppressed GPR109A protein expression ( Figure 6c ). Notably, RANKL robustly increased GPR109A expression ( Figure 6c ). Consistent with inhibitory effects of HA and 3-3-PPA on osteoclastogenic markers, HA and 3-3-PPA significantly inhibited RANKL-induced GPR109A protein expression in RAW264.7 cells (Figure 6c ). Unfortunately, we did not found any differences in RANK gene expression between any concentrations of HA or 3-3-PPA treatment of RAW264.7 cells and untreated control (Figure 6d,e ). GPR109A is a Gi-G protein coupled receptor, and it has been shown that GPR109A reduces accumulation or inactivates intracellular cAMP (Gaidarov et al., 2013; Li et al., 2011) . We finally examined if HA and 3-3-PPA change intracellular second messenger cAMP levels in RAW364.7 cells. RAW264.7 cells were treated with or without 1× HA in the presence or absence of RANKL for 1, 2, 3, and 4 days. Intracellular and cell culture medium cAMP levels were measured by a recently developed and now commercially available ELISA method. RANKL alone significantly decreased intracellular levels of cAMP on days 2, 3, and 4 ( Figure 7a ).
Intracellular cAMP showed a time-dependent increase in cells treated with HA alone (Figure 7a ). With the combination of HA and RANKL treatments, intracellular cAMP levels were back to control levels at each time point (Figure 7a ). cAMP levels in cell culture medium displayed a different pattern than they are intracellular: we found increased cAMP levels in HA-treated cells compared to those untreated controls on Day 2 and 3 (Figure 7b ).
cAMP levels in culture medium were significantly decreased in RANKL-treated wells on Day 4 (Figure 7b ). When RAW364.7 cells were transfected with GPR109A overexpression plasmid (Figure 7c) (three different concentrations, 1× equal to 0.4 pmol/µl of DNA as suggested by manufactory), intracellular cAMP levels were found significantly lower (Figure 7d ). On the other hand, when RAW364.7 cells were transfected with shRNA GPR109A (Figure 7c ; three different concentrations, 1× equal to 12.5 ng/µl of RNA as suggested by manufactory), intracellular cAMP levels were found significantly higher (Figure 7d ). These data indicate that HA or 3-3-PPA inhibits GPR109A expression leads to cAMP accumulation in the cytoplasm to interfere osteoclastogenic signaling (Figure 7e ). Our novel data suggest direct effects of PAs, HA, and 3-3-PPA on inhibiting osteoclastogenesis through a RANKL-RANK independent mechanism. It is known that RANKL is a type II transmembrane protein produced mainly by osteoblasts and other cell types including mesenchymal stromal cells, osteocytes, preadipocytes, and chondrocytes (O'Brien, 2010; Wang et al., 2014) . It is cleaved by proteases to yield soluble form RANKL. Secreted RANKL in turn stimulates preosteoclastic RANK signaling (Feng & Teitelbaum, 2013) and is able to directly induce the differentiation of precursor cells, such as bone marrow-derived macrophages, into mature and active osteoclasts (Feng & Teitelbaum, 2013) . RANKL has its specific decoy receptor, osteoprotegerin (OPG), on the osteoclastic cell surface. After interacting with OPG, RANKL binds to RANK and hence to increase osteoclastogenesis and bone resorption. Using both osteoclastic cell line RAW 264.7 cells and primary nonadherent bone marrow cells, we have shown that HA and 3-3-PPA dose-dependently inhibited osteoclast differentiation and osteoclast resorptive activity. Both HA and 3-3-PPA did not effect on OPG or RANK expression; therefore, their inhibitory effects on osteoclastogenesis do not utilize RANKL/ OPG/RANK mediators. Our data suggest that HA or 3-3-PPA inhibits pre-osteoclast surface GPR109A expression, thus increasing intracellular second messenger cAMP level to suppress expression of osteoclast-specific genes and osteoclast differentiation. The inhibitory effects of HA and 3-3-PPA on this osteoclastogenic pathway has never been proposed before. We did not observe effect of 3-4-PPA within dosages tested on osteoclastogenesis. The structural difference between 3-3-PPA and 3-4-PPA is hydroxyl group in different position of phenyl, we don't know exactly how to explain why 3-3-PPA, but not 3-4-PPA, inhibits osteoclast formation, but possibly is due to different activities binding to GPR109A. molecules that can regulate osteoclastogenesis or inhibit osteoclast activity has been an important clinical goal. It is also important to identify food-based approaches to improve bone health and optimize bone growth. We have previously reported that BB diet suppressed bone resorption by downregulating RANKL expression in stromal cells and/or peroxisome proliferator-activated receptor γ in preadipocytes. We suggested that bone marrow stromal cells are targets for BB diet to regulate RANKL expression and osteoclast differentiation in young rapidly growing rats. In addition, we have also recently reported on the effect of HA on osteoblastic bone formation, and together to our current findings, it appears that HA and 3-3-PPA have effects on anti-osteoclastic cell resorption. Clearly, more in vivo studies are needed, in additional models such as ovariectomized mouse models or collagen-induced rheumatoid arthritis animal models to comprehensively test the hypothesis that HA and 3-3-PPA have value to inhibit bone resorption.
We have previously described that BB diet contains abundant bioactive compounds derived from polyphenols, which mainly include proanthocyanidins, anthocyanidins, flavones, phenolic acid, and stibenes.
PAs are efficiently absorbed and oxidized in the liver and are one of the final metabolites derived from the polyphenols in vivo. HA and 3-3-PPA were identified two phenolic acid metabolites derived from BB pigment polyphenols that appear in the serum of BB diet-fed rats with the highest concentrations (Chen et al., 2010) . Using HPLC/MS, we found that their concentrations were increased with increased percentage of BB consumption in the diet (Zhang et al., 2013) . HA and 3-3-PPA inhibited RANKL-induced osteoclast differentiation in a significant dose-dependent manner. The inhibitory effects of HA and 3-3-PPA were not due to any obvious toxic effects on RAW264.7 cells. Although their synergistic effect will be tested in future studies, HA and 3-3-PPA each significantly suppressed the expression of osteoclastogenesis-related marker genes and proteins. HA and 3-3-PPA significantly inhibited NFATc1 expression, with a subsequent reduction in expression of downstream osteoclastogenic marker genes. As a required protein for RANKL-induced osteoclast formation, a highly phosphorylated form of NFATc1 is in the cytoplasm (Sheridan, Heist, Beals, Crabtree, & Gardner, 2002) , and its expression is regulated by cFos (Mohamed et al., 2007) . Following interactions between RANKL and RANK, NFATc1will be activated and enters into the nucleus to stimulate osteoclast-specific gene expression, including integrin β3, Acp5 (TRAcP), and Ctsk (Crotti et al., 2008 , Matsumoto et al., 2004 . It has been reported that severe bone sclerosis observed in cFos mutant mice is due to the blockage of osteoclast formation (Matsuo et al., 2000) . In addition, it is well recognized that RANKL-RANK interaction results in TNF receptor-associated factor 6 (TRAF6) recruitment and nuclear factor kappa-B, c-Jun amino-terminal kinase, extracellular signalregulated kinase, and p38 signaling pathways activation (Jules, Ashley, & Feng, 2010) . However, further investigations are required to determine if HA and 3-3-PPA inhibit osteoclast differentiation through these subsignaling pathways.
To provide evidence of HA and 3-3-PPA inhibiting osteoclastogenesis through mediators different than RANK in cell membrane of pre-osteoclasts, we examined GPR109A expression | 607 during osteoclast differentiation. We previously determined that HA and 3-3-PPA bind to GPR109A, a G-protein coupled receptor (Ren et al., 2009; Tunaru et al., 2003) . Herein, we were surprised to find that both HA and 3-3-PPA significantly inhibited GPR109A gene expression in pre-osteoclasts in the absence or presence of RANKL. Evidence suggested that activation of GPR109A results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis (Insel, Zhang, Murray, Yokouchi, & Zambon, 2012) . We found that GPR109A gene expression is inhibited by HA and 3-3-PPA resulting in increased levels of intracellular cAMP. It is unknown if the decreased expression of osteoclastic gene markers is the result of a cell type-specific phenomenon or increased levels of intracellular cAMP in pre-osteoclasts by HA and 3-3-PPA.
Intracellular cAMP is known as an important second messenger that mediates a diverse set of extracellular signals, and GPRs evoke cAMP-mediated signaling via Gs (a guanine nucleotidebinding protein related to adenylyl cyclase activation). It was reported that stimulation of cAMP/PKA signaling suppressed osteoclast differentiation (Weivoda et al., 2016) .
In summary, we demonstrated for the first time that HA and 3-3-PPA, PAs found in the highest concentrations in blood from mice fed a BB diet, dose-dependently inhibited osteoclastogenesis through a RANKL/RANK independent mechanism to protect against increased osteoclastic bone resorption. Our data suggested that the effect of HA and 3-3-PPA on osteoclastogenesis is through modulating cell membrane GPR109A to control cAMP levels in cytoplasm and hence osteoclastogenic gene expression. Our current research provides first-ever insights into mechanisms driving the effects of food-derived PAs HA and 3-3-PPA to regulate osteoclastogenesis and bone resorption. (e) Working hypothesis of HA or 3-3-PPA inhibits GPR109A expression leads to cAMP accumulation in the cytoplasm to interfere osteoclastogenic signaling. * ,# Significant differences versus control by t test. Data are means ± standard error with triplicates, time-dependent changes were assessed using Cruzickʼs nonparametric test for trend. cAMP, cyclic adenosine monophosphate; HA, hippuric acid; IL, interleukin; RANKL, receptor activator of nuclear factor κ-Β ligand; shRNA, short hairpin RNA; TNF, tumor necrosis factor
